EGFR and pancreatic neoplasm: A prognostic study in Chinese patients with pancreatic cancer indicated that the median survival rates were 17.2 months and 9.7 months for the EGF (-) EGFR (-) group and EGF (+) EGFR (+) group, respectively [13].